资料显示，一心堂药业集团股份有限公司位于云南省昆明市经济技术开发区鸿翔路1号，成立日期2000 年11月8日，上市日期2014年7月2日，公司主营业务涉及医药零售连锁和医药批发业务。主营业务收入 构成为：中西成药75.03%，其他9.86%，中药8.56%，医疗器械及计生、消毒用品6.55%。 10月20日，一心堂涨0.14%，成交额7764.85万元。两融数据显示，当日一心堂获融资买入额605.06万 元，融资偿还408.48万元，融资净买入196.57万元。截至10月20日，一心堂融资融券余额合计2.15亿 元。 机构持仓方面，截止2025年6月30日，一心堂十大流通股东中，香港中央结算有限公司位居第三大流通 股东，持股1857.44万股，相比上期减少2119.93万股。融通健康产业灵活配置混合A/B（000727）位居 第五大流通股东，持股1328.00万股，相比上期减少272.00万股。广发科技创新混合A（008638）位居第 六大流通股东，持股1231.72万股，为新进股东。广发创新升级混合（002939）位居第七大流通股东， 持股749.40万股，为新进股东。广发价值核心混合A（010377）位居 ...

Core Viewpoint - YXTT's stock price has shown fluctuations in recent trading sessions, with a year-to-date increase of 16.53% but a recent decline of 1.00% over the last five trading days [2] Group 1: Stock Performance - As of September 11, YXTT's stock price was 14.83 CNY per share, with a market capitalization of 8.685 billion CNY [1] - The stock has experienced a 2.05% decline during the trading session on September 11, with a trading volume of 41.0343 million CNY and a turnover rate of 0.69% [1] - Year-to-date, YXTT has appeared on the "Dragon and Tiger List" twice, with the most recent appearance on May 23, where it recorded a net buy of -4.0951 million CNY [2] Group 2: Financial Performance - For the first half of 2025, YXTT reported a revenue of 8.914 billion CNY, a year-on-year decrease of 4.20%, and a net profit attributable to shareholders of 250 million CNY, down 11.44% year-on-year [2] - Cumulative cash dividends since YXTT's A-share listing amount to 1.908 billion CNY, with 649 million CNY distributed over the past three years [3] Group 3: Shareholder Structure - As of June 30, 2025, YXTT had 33,900 shareholders, a decrease of 5.42% from the previous period, with an average of 11,712 circulating shares per shareholder, an increase of 5.73% [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 18.5744 million shares, a decrease of 21.1993 million shares from the previous period [3] - New entrants among the top ten shareholders include several funds, such as Guangfa Technology Innovation Mixed Fund and Invesco Great Wall Growth Star Stock A [3]